Physician profile
Robert Otte
NPI 1386689305
$1,167.88
in general payments reported to CMS, 2019-2025
11 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $28.61 · 2021: $100 · 2022: $365 · 2023: $239 · 2024: $179 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $326.80 | 2022-2023 | Tezspire |
| Genentech USA, INC. | $130.76 | 2019 | |
| Abbvie INC. | $129.03 | 2022-2023 | |
| Grifols USA, LLC | $124.99 | 2025 | Xembify |
| Blueprint Medicines Corporation | $124.46 | 2024 | Ayvakit |
| Pharming Healthcare, INC. | $103.43 | 2022 | |
| Genzyme Corporation | $100.33 | 2021 | |
| Novo Nordisk INC | $57.60 | 2023-2024 | Wegovy |
| Csl Behring | $28.61 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $26.77 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $15.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Otte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.